Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Randomized, Multicenter Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer

Trial Profile

A Phase II, Randomized, Multicenter Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Glembatumumab vedotin (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms EMERGE
  • Sponsors Celldex Therapeutics Inc

Most Recent Events

  • 27 Sep 2015 Results of post-hoc analysis (n=328) presented at the ASCO - Breast Cancer Symposium 2015
  • 06 Apr 2015 According to a Celldex Therapeutics media release, the data from this study supported the initiation of the phase 2 METRIC study. (See CT profile 700239414)
  • 06 Apr 2015 Results published in a Celldex Therapeutics media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top